For the year ending 2025-12-31, SRTAW had $11,585K increase in cash & cash equivalents over the period. -$58,509K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income / (loss) | 41,347 |
| Gain on sale of business | 56,996 |
| Depreciation and amortization | 8,185 |
| Stock-based compensation | 17,832 |
| Change in fair value of warrant liabilities | -4,278 |
| Change in fair value of assets and other liabilities | 1,037 |
| Excess of lease liability over operating right-of-use assets | 0 |
| Transaction costs paid related to sale of business | 7,381 |
| Gain on lease modification | 0 |
| Acquisition consideration allocated to seller transaction expenses | 44,339 |
| Impairment of intangible assets | 0 |
| Impairment of property and equipment | 1,673 |
| Realized loss from sale of short-term investments | -5,195 |
| Realized foreign exchange gain | 798 |
| Accretion of interest income on held-to-maturity securities | 2,214 |
| Deferred tax expense (benefit) | 432 |
| Other | 471 |
| Prepaid expenses and other current assets | 1,686 |
| Accounts receivable | 12,034 |
| Other non-current assets | -666 |
| Operating right-of-use assets/lease liabilities | 88 |
| Accounts payable and accrued expenses | 2,378 |
| Deferred revenue | 1,684 |
| Net cash used in operating activities | -48,914 |
| Acquisitions, net of cash acquired | 66,535 |
| Cash transfer from sale of business | 2,810 |
| Capitalized software development costs | 1,415 |
| Purchase of property and equipment, net of proceeds from disposal | 9,595 |
| Purchase of held-to-maturity investments | 146,258 |
| Proceeds from maturities of held-to-maturity investments | 226,200 |
| Proceeds from sale of short-term investments | 70,163 |
| Net cash provided by / (used in) investing activities (includes discontinued operations see note 5) | 69,750 |
| Proceeds from the exercise of common stock options | 193 |
| Taxes paid related to net share settlement of equity awards | 9,105 |
| Repurchase and retirement of common stock | 0 |
| Net cash used in financing activities | -8,912 |
| Effect of foreign exchange rate changes on cash balances | -339 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 11,585 |
| Cash and cash equivalents and restricted cash - beginning | 19,647 |
| Cash and cash equivalents and restricted cash - ending | 31,232 |
Strata Critical Medical, Inc. (SRTAW)
Strata Critical Medical, Inc. (SRTAW)